Immuron to Commence Non-Deal Investor Roadshow
August 16 2019 - 06:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunoglobulin therapeutics for the treatment of gut mediated
diseases, today is pleased to release to shareholders and investors
its latest Company Update presentation ahead of a comprehensive
roadshow to investment institutions, analysts and shareholders, by
CEO Dr. Gary Jacob.
A presentation accompanying this announcement
can be found
at: http://ml.globenewswire.com/Resource/Download/80f633ae-55eb-4635-bfc1-39a6814613c3
ABOUT IMMURON:Immuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious
diseases. Immuron has a novel and safe technology platform with one
commercial asset generating revenue. In Australia, Travelan® is a
listed medicine on the Australian Register of Therapeutic Goods
(AUST L 106709) and is indicated to reduce the risk of Travellers’
Diarrhea, reduce the risk of minor gastro-intestinal disorders and
is antimicrobial. In Canada, Travelan® is a licenced natural health
product (NPN 80046016) and is indicated to reduce the risk of
Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary
supplement for digestive tract protection in accordance with
section 403 (r)(6) of the Federal Drug Administration (FDA). The
company now has plans to develop a U.S. registration dossier for
IMM-124E for Travellers’ Diarrhea. Immuron’s second clinical-stage
asset, IMM-529, targets Clostridium difficile Infections (CDI), and
is presently in a clinical trial in CDI patients. These products
together with the Company’s other preclinical immunotherapeutic
assets currently under development targeting infectious diseases
are anticipated to meet pressing needs in the global immunotherapy
market.
For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited
to, any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
COMPANY CONTACT:
Gary S. Jacob, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
AUS INVESTOR RELATIONS:
Peter Taylor
NWR Communications
Ph: +61 (0)4 1203 6231
peter@nwrcommunications.com.au
USA INVESTOR RELATIONS:
Dave Gentry - CEO
RedChip Companies, Inc.
US Ph: +1 (407) 491 4498
dave@redchip.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2023 to Mar 2024